NASDAQ$TERN
Terns Pharmaceuticals Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Terns reported positive top-line data from the Phase 2a DUET trial and highlighted TERN-601 program in obesity.
Terns Pharmaceuticals reported its Q2 2023 financial results, featuring positive data from the Phase 2a DUET trial of TERN-501 in NASH and updates on its TERN-701 and TERN-601 programs. The company's cash, cash equivalents, and marketable securities are expected to provide runway into 2026.
- TERN-501 met all primary and secondary endpoints in Phase 2a DUET trial.
- TERN-701 Phase 1 clinical trial for CML is on track to start in the second half of 2023.
- TERN-601 program in obesity highlighted with Phase 1 clinical trial planned for the second half of 2023.
- Cash, cash equivalents and marketable securities of $285.6 million expected to provide runway into 2026.
Headline financials
Revenue & EPS history
Terns · Revenue · Quarterly
$0
Forward guidance
Terns Pharmaceuticals is focused on advancing its pipeline, with upcoming milestones including initiating Phase 1 studies for TERN-701 and TERN-601 in the second half of the year and a Phase 2b trial of TERN-501 in NASH.
Tailwinds
- TERN-501 showed dose dependent and statistically significant reductions in liver fat content and fibro-inflammation.
- TERN-501 demonstrated a class-leading safety and tolerability profile.
- TERN-701 outperformed asciminib in certain xenograft mouse models.
- TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in transgenic mice.
- Cash, cash equivalents and marketable securities expected to provide runway into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+16.4%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+19.8%
Q4 2022
Best reaction
-23.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.3% | -0.0% | — | |
| Q3 2025 | +7.6% | +18.0% | +146.3% | |
| Q2 2025 | -6.8% | +3.6% | +18.7% | |
| Q1 2025 | -0.7% | -4.1% | +22.3% | |
| Q4 2024 | -2.7% | -1.3% | -23.6% | |
| Q3 2024 | -9.1% | -17.3% | -11.7% | |
| Q2 2024 | -4.6% | -11.8% | -1.7% | |
| Q1 2024 | +7.7% | +6.1% | +32.9% | |
| Q4 2023 | +1.7% | -15.0% | -27.4% | |
| Q3 2023 | +14.2% | +10.1% | +92.3% | |
| Q2 2023 | -9.5% | +0.8% | -21.5% | |
| Q1 2023 | -15.2% | -20.3% | -7.0% | |
| Q4 2022 | +19.8% | +32.7% | +42.3% | |
| Q3 2022 | -23.0% | -26.7% | -12.2% | |
| Q2 2022 | -5.5% | +39.2% | +75.1% | |
| Q1 2022 | +4.0% | -0.7% | +26.5% | |
| Q4 2021 | +4.1% | +3.5% | -5.4% | |
| Q3 2021 | -1.2% | -5.9% | -30.9% | |
| Q2 2021 | +4.3% | +3.5% | -0.9% | |
| Q1 2021 | +3.6% | +5.6% | +13.5% | |
| Q4 2020 | +5.8% | -0.9% | +1.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro